Internal Medicine, Cardiovascular Disease · Brownsville, TX
NPI
1588659890
Since 2005
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
213 Heart Drive
Brownsville, TX, 78520
Phone (956) 504-3278
Groups this clinician bills Medicare through
Medicare paid, 2024
$180K
6,437 services
Medicare patients, 2024
575
Average age 77
Drug cost, 2024
$876K
6,687 prescriptions
Company payments, 2025
$678
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Roberto B Robles was code Q9967 (low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml), 3,411 times for 28 patients. In total Roberto B Robles billed 6,437 services in 120 codes, and Medicare paid $180K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-07-07.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 3,411 | 28 | $0.11 | $361 |
| 99214 Office E&M - Established | Office | 687 | 238 | $94.21 | $65K |
| J2785 Injection, regadenoson, 0.1 mg | Office | 220 | 55 | $6.05 | $1,332 |
| 93306 Echocardiography (TTE/TEE) | Office | 170 | 168 | $130.48 | $22K |
| 93000 Electrocardiogram | Office | 162 | 151 | $11.19 | $1,812 |
| 71046 X-ray - Chest | Office | 95 | 89 | $23.40 | $2,223 |
| 85610 Clinical Chemistry | Office | 81 | 17 | $4.20 | $340 |
| 99213 Office E&M - Established | Office | 76 | 62 | $59.49 | $4,521 |
| A9500 Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 69 | 63 | $66.18 | $4,567 |
| 78452 Myocardial Perfusion Scan | Office | 67 | 67 | $335.24 | $22K |
| 93016 Electrocardiogram | Office | 67 | 67 | $16.93 | $1,134 |
| 93017 Electrocardiogram | Office | 67 | 67 | $22.43 | $1,503 |
| 93018 Electrocardiogram | Office | 67 | 67 | $11.20 | $750 |
| 99211 Office E&M - Established | Office | 56 | 15 | $16.14 | $904 |
| 96372 Injection Administration | Office | 44 | 31 | $9.59 | $422 |
By year: 2022 $207K for 5,967 services; 2023 $194K for 5,747 services; 2024 $180K for 6,437 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85610 Clinical Chemistry | 81 | 17 | $4.20 | $340 |
| 36415 Venipuncture Blood Collection | 35 | 31 | $8.65 | $303 |
| 87804 Immunoassay | 26 | 13 | $16.22 | $422 |
| 85025 Blood Count | 23 | 22 | $7.61 | $175 |
| 87426 Immunoassay | 13 | 13 | $34.62 | $450 |
| 87880 Immunoassay | 11 | 11 | $16.20 | $178 |
Medicare prescription drug claims, 2024
In 2024, the drug Roberto B Robles prescribed most often to Medicare patients was Carvedilol, with 586 prescriptions and refills. In total Roberto B Robles wrote 6,687 Medicare prescriptions that cost $876K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carvedilol Generic | 586 | 1,464 | 198 | $4,311 |
| Amlodipine Besylate Generic | 533 | 1,369 | 204 | $2,584 |
| Olmesartan-Hydrochlorothiazide Olmesartan/Hydrochlorothiazide | 503 | 1,226 | 184 | $14K |
| Atorvastatin Calcium Generic | 306 | 838 | 116 | $2,931 |
| Losartan Potassium Generic | 253 | 609 | 97 | $2,203 |
| Rosuvastatin Calcium Generic | 249 | 686 | 83 | $3,011 |
| Metoprolol Succinate Generic | 221 | 606 | 84 | $2,553 |
| Olmesartan Medoxomil Generic | 197 | 506 | 73 | $2,907 |
| Xarelto Rivaroxaban | 156 | 319 | 48 | $184K |
| Entresto Sacubitril/Valsartan | 155 | 284 | 45 | $184K |
| Eliquis Apixaban | 136 | 254 | 41 | $150K |
| Clopidogrel Clopidogrel Bisulfate | 136 | 395 | 53 | $1,410 |
| Metformin Hcl Generic | 129 | 364 | 48 | $649 |
| Atenolol Generic | 121 | 307 | 44 | $557 |
| Ezetimibe Generic | 116 | 292 | 41 | $3,699 |
Brand drugs: 833 claims; generic drugs: 5,837 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Roberto B Robles $678 ($678 in general payments such as food, travel and fees) from 11 companies. The largest payer was Lilly USA, LLC with $146.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 4 | $146 |
| Biotronik Inc. | 1 | $112 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $109 |
| Merck Sharp & Dohme LLC MRK | 5 | $99.74 |
| Pfizer Inc. PFE | 3 | $53.49 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37.86 |
| Novo Nordisk Inc NVO | 2 | $34.89 |
| GlaxoSmithKline, LLC. GSK | 1 | $32.8 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $18.96 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $17.42 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.